University of New Hampshire Library Annual Report, 2016-2017

The 2016–2017 year was one of continued transformation for the UNH Library. The library continued to define their role as the flagship academic library for New Hampshire while broadening and deepening their contributions to support teaching, research, and service for the campus

Chromogranin A in the olfactory system of the rat

The olfactory bulb of the rat contains chromogranin A at a similar level as the adrenal gland or the hypophysis as revealed by immunoblots. Olfactory chromogranin A also displays the same size as chromogranin A of endocrine cells. In the hippocampus and other brain regions, we could not detect chromogranin A by immunoblotting. In contrast, chromogranin A messenger ribonucleic acid (using S1 nuclease protection assays) was observed in all brain regions examined, including the olfactory bulb. By in situ hybridization histochemistry with a complementary ribonucleic acid probe (280 nucleotides), and by immunocytochemistry, chromogranin A synthesis could be localized to cell bodies of the mitral cell layer, of the external plexiform layer and of the periglomerular region of the olfactory bulb. Immunocytochemically, chromogranin A was also detected in the central projection areas of mitral and tufted cells in the primary olfactory cortex and the anterior amygdaloid area but not in the olfactory glomeruli, where the incoming olfactory nerve fibers of the primary olfactory neurons establish synaptic contacts. Taken together the data show that chromogranin A, following biosynthesis in the perikarya of the mitral and tufted cells, is specifically transported into their axonal terminals but not into their primary dendrites. We propose that the rat olfactory system could serve as a model for the study of chromogranin A regulation and function in neurons

Optimization of Drug Delivery by Drug-Eluting Stents

International audienceDrug-eluting stents (DES), which release anti-proliferative drugs into the arterial wall in a controlled manner, have drastically reduced the rate of in-stent restenosis and revolutionized the treatment of atherosclerosis. However, late stent thrombosis remains a safety concern in DES, mainly due to delayed healing of the endothelial wound inflicted during DES implantation. We present a framework to optimize DES design such that restenosis is inhibited without affecting the endothelial healing process. To this end, we have developed a computational model of fluid flow and drug transport in stented arteries and have used this model to establish a metric for quantifying DES performance. The model takes into account the multi-layered structure of the arterial wall and incorporates a reversible binding model to describe drug interaction with the cells of the arterial wall. The model is coupled to a novel optimization algorithm that allows identification of optimal DES designs. We show that optimizing the period of drug release from DES and the initial drug concentration within the coating has a drastic effect on DES performance. Paclitaxel-eluting stents perform optimally by releasing their drug either very rapidly (within a few hours) or very slowly (over periods of several months up to one year) at concentrations considerably lower than current DES. In contrast, sirolimus-eluting stents perform optimally only when drug release is slow. The results offer explanations for recent trends in the development of DES and demonstrate the potential for large improvements in DES design relative to the current state of commercial devices

A comparative study of Rayleigh-Taylor and Richtmyer-Meshkov instabilities in 2D and 3D in tantalum

Driving a shock wave through the interface between two materials with different densities can result in the Richtmyer-Meshkov or Rayleigh-Taylor instability and initial perturbations at the interface will grow. If the shock wave is sufficiently strong, the instability will lead to plastic flow at the interface. Material strength will reduce the amount of plastic flow and suppress growth. While such instabilities have been investigated in 2D, no studies of this phenomena have been performed in 3D on materials with strength. Initial perturbations to seed the hydrodynamic instability were coined into tantalum recovery targets. Two types of perturbations were used, two dimensional (2D) perturbations (hill and valley) and three-dimensional (3D) perturbations (egg crate pattern). The targets were subjected to dynamic loading using the Janus laser at the Jupiter Laser Facility. Shock pressures ranged from 50 GPa up to 150 GPa and were calibrated using VISAR drive targets

Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease

Fifty‐nine patients with prior hepatitis B virus infection underwent orthotopic liver transplantation. During the first 2 mo, mortality was not significantly different in the hepatitis B virus–infected group (25.5%) vs. a hepatitis B virus–immune control group (21%). Beyond 2 mo, the mortality, rate of graft loss, need for retransplantation and incidence of abnormal liver function were significantly higher in the hepatitis B virus–infected group. Treatment of the hepatitis B virus infection was attempted with passive immunization, combined active and passive immunization, α‐interferon or nothing. The clinical outcome was not significantly influenced by any of these therapies. However, of the patients who lived more than 60 days, 6 of 22 treated with active plus passive immunization were cleared of HBsAg, something achieved once in 16 patients treated with α‐interferon, never in 3 patients with passive immunization only and once in 4 patients with no therapy. In patients with recurrent hepatitis B virus infection, the pace of hepatitis development in the graft appeared to be accelerated, and this was particularly striking in patients who underwent multiple retransplantations at progressively shorter intervals. None of the patients who became HBsAg‐negative had HBeAg preoperatively. (HEPATOLOGY 1991;13:619–626.) Copyright © 1991 American Association for the Study of Liver Disease

Immunological characterization of chromogranins A and B and secretogranin II in the bovine pancreatic islet

Antisera against chromogranin A and B and secretogranin II were used for analysing the bovine pancreas by immunoblotting and immunohistochemistry. All three antigens were found in extracts of fetal pancreas by one dimensional immunoblotting. A comparison with the soluble proteins of chromaffin granules revealed that in adrenal medulla and in pancreas antigens which migrated identically in electrophoresis were present. In immunohistochemistry, chromogranin A was found in all pancreatic endocrine cell types with the exception of most pancreatic polypeptide-(PP-) producing cells. For chromogranin B, only a faint immunostaining was obtained. For secretorgranin II, A-and B-cells were faintly positive, whereas the majority of PP-cells exhibited a strong immunostaining for this antigen. These results establish that chromogranins A and B and secretogranin II are present in the endocrine pancreas, but that they exhibit a distinct cellular localization

Review of Putting Descriptive Standards to Work

For a thorough understanding of current descriptive best practices, consult Putting Descriptive Standards to Work, edited by Kris Kiesling and Christopher J. Prom, with modules written by Cory L. Nimer, Kelcy Shepherd, Katherine M. Wisser, and Aaron Rubinstein. This volume covers modules seventeen through twenty of the Trends in Archives Practice series from the Society of American Archivists. The book provides readers with the context and the applied examples needed to explore the possibilities of descriptive standards